Status:
COMPLETED
Ganglioside and IBD
Lead Sponsor:
Children's Hospital of Orange County
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
9-21 years
Phase:
NA
Brief Summary
Context. Inflammatory bowel disease (IBD) is a chronic and debilitating disorder. Novel treatment strategies aimed to resolve intestinal inflammation and induce disease remission are necessary. Dietar...
Eligibility Criteria
Inclusion
- Participants age 9-21 years
- Mild-moderate IBD defined by ImproveCareNow (ICN) Physician Global Assessment (PGA); OR severe IBD defined by ICN PGA if stable for at least 120 days
- Ileal, ileocolonic, colonic location of disease
Exclusion
- Pregnancy
- Previous bowel resection
- Non-ileocolonic location of disease
- Inadequate liver or renal function
- On prescription medication for active infectious disease
- Drug/alcohol abuse
- Other serious medical conditions
Key Trial Info
Start Date :
June 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 24 2024
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04782544
Start Date
June 28 2021
End Date
March 24 2024
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Orange County
Orange, California, United States, 92868